

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP2005/000176

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/07 A61K31/05 A61P27/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/004058 A (SANTEN PHARMACEUTICAL CO., LTD; EISAI CO., LTD; MIYAWAKI, NOBUAKI; HAR) 16 January 2003 (2003-01-16) abstract	1-6, 53-65
A	EP 0 522 226 A (COSTAGLIOLA, CIRO) 13 January 1993 (1993-01-13) page 1, line 10 - line 15	1-6, 53-65
A	US 2003/032078 A1 (TRAVIS GABRIEL H) 13 February 2003 (2003-02-13) figure 6 page 1, paragraph 2	
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

27 September 2005

Date of mailing of the international search report

05/10/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bonzano, C

INTERNATIONAL SEARCH REPORT

Inter. al Application No
PC. 2005/000176

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WROBEL A ET AL: "Antiangiogenic activity of agonist and antagonists of retinoid nuclear receptors" PRZEGLAD DERMATOLOGICZNY 1999 POLAND, vol. 86, no. 4, 1999, pages 339-346, XP000879096 ISSN: 0033-2526 abstract page 342, paragraph 2</p>	1-6, 53-65
A	<p>MARMOR M F ET AL: "Albipunctate retinopathy with cone dysfunction and no abnormality in the RDH5 or RLBP1 genes" RETINA 2003 UNITED STATES, vol. 23, no. 4, 2003, pages 543-546, XP008049556 ISSN: 0275-004X page 543, column 2, paragraph 1 - paragraph 2</p>	24
A	<p>WELEBER R G ET AL: "Abnormal retinal function associated with isotretinoin therapy for acne" ARCHIVES OF OPHTHALMOLOGY 1986 UNITED STATES, vol. 104, no. 6, 1986, pages 831-837, XP008049560 page 831, column 2, paragraph 2 page 837, column 2, paragraph 2</p>	
A	<p>CALISSENDORFF B M: "RETINAL CHANGES DEGENERATION OR SIDE EFFECTS CAUSED BY ETRETINATE THERAPY TIGASON" KLINISCHE MONATSBLAETTER FUER AUGENHEILKUNDE, vol. 194, no. 3, 1989, pages 187-189, XP008049557 ISSN: 0023-2165 page 188, column 1, paragraph 1</p>	
E	<p>WO 2005/056010 A (ALLERGAN, INC; WHITCUP, SCOTT, M; CHANDRARATNA, ROSHANTHA, A; LAI, RON) 23 June 2005 (2005-06-23) claims 1,14 page 1, paragraph 2 - paragraph 3 page 2, paragraph 1</p>	1,39-47
P,A	<p>WO 2005/011741 A (ALLERGAN, INC; HUGHES, PATRICK, M; OLEJNIK, CREST) 10 February 2005 (2005-02-10) page 11, line 5 - line 11 examples 1-4 claims 1,13</p>	1-7
	-/--	

INTERNATIONAL SEARCH REPORT

Intern il Application No
PCT, ...2005/000176

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OIKAWA T ET AL: "THREE NOVEL SYNTHETIC RETINIDS, RE 80, AM 580 AND AM 80, ALL EXHIBIT ANTI-ANGIOGENIC ACTIVITY IN VIVO" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 249, no. 1, November 1993 (1993-11), pages 113-116, XP000879175 ISSN: 0014-2999 page 113, column 1 figure 1	1-5,7, 25-27
X	US 5 824 685 A (CAMPOCHIARO ET AL) 20 October 1998 (1998-10-20) column 16; table 3	1-29, 39-47, 53-65